砥礪前行，從三大權威指南看T-DXd在HER2陽性晚期胃癌中強勢發展( 五 ) _健康小知識

[16]SatohT,XuRH,ChungHC,etal.Lapatinibpluspaclitaxelversuspaclitaxelaloneinthesecond-linetreatmentofHER2-amplifiedadvancedgastriccancerinAsianpopulations:TyTAN--arandomized,phaseIIIstudy.JClinOncol.2014Jul1;32(19):2039-49.
[17]Thuss-PatiencePC,ShahMA,OhtsuA,etal.TrastuzumabemtansineversustaxaneuseforpreviouslytreatedHER2-positivelocallyadvancedormetastaticgastricorgastro-oesophagealjunctionadenocarcinoma(GATSBY):aninternationalrandomised,open-label,adaptive,phase2/3study.LancetOncol.2017May;18(5):640-653.
[18]MakiyamaA,SukawaY,KashiwadaT,etal.Randomized,PhaseIIStudyofTrastuzumabBeyondProgressioninPatientsWithHER2-PositiveAdvancedGastricorGastroesophagealJunctionCancer:WJOG7112G(T-ACTStudy).JClinOncol.2020Jun10;38(17):1919-1927.
[19]CatenacciDVT,KangYK,ParkH,etal.Margetuximabpluspembrolizumabinpatientswithpreviouslytreated,HER2-positivegastro-oesophagealadenocarcinoma(CP-MGAH22-05):asingle-arm,phase1b-2trial.LancetOncol.2020Aug;21(8):1066-1076.
[20]PrimaryAnalysisofaPhase2Single-ArmTrialofTrastuzumabDeruxtecan(T-DXd)inWesternPatientsWithHER2-Positive(HER2+)UnresectableorMetastaticGastricorGastroesophagealJunction(GEJ)CancerWhoProgressedonorAfteraTrastuzumab-containingRegimen.2021ESMO.AbstractLBA55.
[22]https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.TPS371.
[24]JRHecht,YJBang,SKQin,etal.LapatinibinCombinationWithCapecitabinePlusOxaliplatininHumanEpidermalGrowthFactorReceptor2-PositiveAdvancedorMetastaticGastric,Esophageal,orGastroesophagealAdenocarcinoma:TRIO-013/LOGiC--ARandomizedPhaseIIITrial.JClinOncol,2016.34(5):443-51.
[25]JTabernero,PMHoff,LShen,etal.PertuzumabplustrastuzumabandchemotherapyforHER2-positivemetastaticgastricorgastro-oesophagealjunctioncancer(JACOB):finalanalysisofadouble-blind,randomised,placebo-controlledphase3study.LancetOncol,2018.19(10):1372-84.
[26]JanjigianYY,KawazoeA,Ya?ezP,etal.TheKEYNOTE-811trialofdualPD-1andHER2blockadeinHER2-positivegastriccancer.Nature.2021Dec;600(7890):727-730.
[27]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-trastuzumab-fluoropyrimidine
[28]Dose-escalationanddose-expansionstudyoftrastuzumabderuxtecan(T-DXd)monotherapyandcombinationsinpatientswithadvanced/metastaticHER2-positivegastriccancer/gastroesophagealjunctionadenocarcinoma:DESTINY-Gastric03.2022ASCOGIPoster295.
熱文推薦

文章圖片

文章圖片

文章圖片

文章圖片

文章圖片
*醫學界力求其發表內容在審核通過時的準確可靠，但并不對已發表內容的適時性，以及所引用資料（如有）的準確性和完整性等作出任何承諾和保證，亦不承擔因該些內容已過時、所引用資料可能的不準確或不完整等情況引起的任何責任。請相關各方在采用或者以此作為決策依據時另行核查。